The potential of CTLA-4 blockade to mobilize anti-tumor immunity has been recapitulated in clinical trials for human melanoma and other solid tumors [29-31], and in 2011 a monoclonal anti-CTLA-4 antibody (Ipilimumab) received FDA approval for the treatment of patients with advanced melanoma. This evidence concerns the gene CTLA4 and melanoma.